Grufity logoGrufity logo

ZY

Market Closed

Zymergen Inc.

ZY Stock Price

RSI Chart

Valuation

Market Cap

253.0M

Price/Earnings

-0.69

Price/Sales

17.39

Price/Cashflow

-1.08

MarketCap/EBT

-0.69

Price/Sales

Profitability

EBT Margin

-2508.64%

Return on Equity

-154.23%

Return on Assets

-77.49%

Fundamentals

Revenue

Revenue (TTM)

14.5M

Revenue Y/Y

-55.26%

Revenue Q/Q

-45.02%

Earnings

Earnings (TTM)

-365.0M

Earnings Y/Y

-15.51%

Earnings Q/Q

-61.5%

Price Action

Last 7 days

-8.6%

Last 30 days

-8.6%

Last 90 days

13.0%

Trailing 12 Months

-80.7%

Financial Health

Current Ratio

4.59

Investor Care

Shares Dilution (1Y)

1.67%

Diluted EPS (TTM)

-3.28

Financials for Zymergen

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue-18.3%1518172019
  S&GA Expenses-23.2%1620242323
  R&D Expenses-12.8%129148159159142
Earnings Before Taxes-4.5%-364.91-349.33-361.73-359.25-322.82
Net Income-4.5%-364.95-349.32-361.78-359.24-322.83
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-23.8%471618522627725
  Current Assets-32.2%240354407517606
    Cash Equivalents-36.6%214337386496578
  Inventory1.9%66666
  Net PPE26.0%7156545562
  Goodwill-100.0%-41413434
Liabilities-14.5%234274114151156
  Current Liabilities-41.0%52887412152
    LT Debt, Current-100.0%-514480-
    LT Debt, Non CurrentNaN%---80-
Shareholder's Equity-31.2%237344408477569
  Retained Earnings-8.3%-1,300.00-1,200.00-1,135.53-1,057.39-959.16
  Additional Paid-In Capital0.6%1,5611,5521,5441,5341,528
Accumulated Depreciation5.0%8379787356
Shares Outstanding0.7%104103103102102
Float-2,100----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations11.1%-234.94-264.16-302.46-299.65-272.55
  Share Based Compensation6.3%2826211612
Cashflow From Investing5.3%-26.74-28.24-32.20-26.03-22.27
Cashflow From Financing-119.4%-98.78510514746850

Risks

What is the probability of a big loss on ZY?

96.2%


Probability that Zymergen stock will be more than 20% underwater in next one year

96.2%


Probability that Zymergen stock will be more than 30% underwater in next one year.

81.0%


Probability that Zymergen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ZY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Zymergen was unfortunately bought at previous high price.

Returns

Cumulative Returns on ZY

Which funds bought or sold ZY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
804
1,000
-%
2022-11-22
B. Riley Wealth Advisors, Inc.
NEW
-
261,000
261,000
0.01%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-1,000
-
-%
2022-11-15
ALLIANCEBERNSTEIN L.P.
UNCHANGED
-
23,000
41,000
-%
2022-11-15
JANE STREET GROUP, LLC
REDUCED
-47.22
17,000
106,000
-%
2022-11-15
Balyasny Asset Management LLC
SOLD OFF
-100
-22,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
STATE STREET CORP
ADDED
170.08
356,000
426,000
-%
2022-11-15
Anson Funds Management LP
NEW
-
92,000
92,000
0.01%
2022-11-15
NOMURA HOLDINGS INC
NEW
-
39,000
39,000
-%

1–10 of 43

Latest Funds Activity

Are funds buying ZY calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ZY

Zymergen News

StockNews.com

DNA: 3 F-Rated Stocks to Sell Now Rather Than Later.16 days ago

GuruFocus.com

ZY Fair Value

Recent SEC filings of Zymergen

View All Filings
Date Filed Form Type Document
Oct 31, 2022
15-12G
15-12G
Oct 25, 2022
EFFECT
EFFECT
Oct 21, 2022
4
Insider Trading
Oct 21, 2022
SC 13G/A
Major Ownership Report
Oct 19, 2022
4
Insider Trading
Oct 19, 2022
4
Insider Trading
Oct 19, 2022
4
Insider Trading
Oct 19, 2022
4
Insider Trading
Oct 19, 2022
4
Insider Trading
Oct 19, 2022
4
Insider Trading

Latest Insider Trading transactions for ZY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-19
Murdoch Travis
GIVEN BACK TO IS
-
-
-79,697
-
2022-10-19
Ocko Matthew
GIVEN BACK TO IS
-
-
-7,366,630
-
2022-10-19
SVF Excalibur (Cayman) Ltd
SOLD
-
-
-26,614,200
-
2022-10-19
Serber Zachariah
GIVEN BACK TO IS
-
-
-40,000
-
2022-10-19
Singh Enakshi
GIVEN BACK TO IS
-
-
-462,241
Chief Financial Officer
2022-10-19
FLATLEY JAY T
GIVEN BACK TO IS
-
-
-144,789
Chairman and Acting CEO
2022-10-19
PETERSON SANDRA E
GIVEN BACK TO IS
-
-
-119,119
-
2022-10-19
Serber Zachariah
GIVEN BACK TO IS
-
-
-2,551,680
-
2022-10-19
Chu Steven
GIVEN BACK TO IS
-
-
-50,000
-
2022-10-19
Gorjanc Christine Marie
GIVEN BACK TO IS
-
-
-50,000
-

1–10 of 50

Jay T. Flatley
510
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California.

ZY Income Statement

2022-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues$ 2,634$ 5,854$ 7,425$ 9,589
Cost and operating expenses:    
Research and development31,18650,15259,92589,963
Sales and marketing3,1587,9046,79614,776
General and administrative24,29423,66147,99942,992
Goodwill impairment charge40,645040,6450
Restructuring charges (benefit)(185)0(315)0
Total cost and operating expenses108,830103,546177,237190,690
Operating loss(106,196)(97,692)(169,812)(181,101)
Other income (expense):    
Interest income2125355
Interest expense(9,378)(2,767)(17,423)(5,494)
Gain (loss) on change in fair value of warrant liabilities0(430)01,849
Other expense, net(885)(5)(1,417)(768)
Total other expense(10,261)(3,190)(18,787)(4,358)
Loss before income taxes(116,457)(100,882)(188,599)(185,459)
Benefit from (provision for) income taxes(11)16158
Net loss and comprehensive loss(116,468)(100,866)(188,584)(185,451)
Net loss and comprehensive loss$ (116,468)$ (100,866)$ (188,584)$ (185,451)
Net loss per share attributable to common stockholders, basic (in dollars per share)$ (1.13)$ (1.30)$ (1.83)$ (4.07)
Net loss per share attributable to common stockholders, diluted (in dollars per share)$ (1.13)$ (1.30)$ (1.83)$ (4.10)
Weighted average shares used in computing net loss per share to common stockholders, basic (in shares)103,482,90777,671,643103,297,07045,512,654
Weighted average shares used in computing net loss per share to common stockholders, diluted (in shares)103,482,90777,671,643103,297,07045,727,153
Revenues from research and development service agreements    
Revenues$ 1,191$ 4,846$ 4,412$ 7,460
Collaboration and other revenue    
Revenues7461,0082,0792,129
Automation revenue    
Revenues48004800
Cost and operating expenses:    
Cost of revenue63706370
Grant revenue    
Revenues21704540
Service revenue    
Cost and operating expenses:    
Cost of revenue$ 9,095$ 21,829$ 21,550$ 42,959

ZY Balance Sheet

2022-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 213,558$ 386,105[1]
Accounts receivable1,272520[1]
Accounts receivable, unbilled2,4242,565[1]
Prepaid expenses11,8147,818[1]
Inventories6,1076,035[1]
Restricted cash, current2,9972,105[1]
Other current assets1,4692,201[1]
Total current assets239,641407,349[1]
Restricted cash10,0169,849[1]
Property and equipment, net70,59053,799[1]
Operating lease right-of-use assets141,105 
Goodwill040,645[1]
Intangible assets, net7,3808,529[1]
Other long-term assets2,2362,225[1]
Total assets470,968522,396[1]
Current liabilities:  
Accounts payable12,8775,418[1]
Accrued and other liabilities27,00917,496[1]
Short-term operating lease liabilities7,900 
Short-term debt, net043,953[1]
Short-term deferred rent02,218[1]
Deferred revenue4,4104,468[1]
Total current liabilities52,19673,553[1]
Long-term operating lease liabilities178,181 
Long-term deferred rent035,390[1]
Other long-term liabilities3,9684,967[1]
Total liabilities234,345113,910[1]
Commitments and contingencies[1]
Stockholders' equity  
Preferred stock, $0.001 par value, 170,000,000 authorized as of June 30, 2022 and December 31, 2021, respectively; no shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively00[1]
Common stock, $0.001 par value, 1,500,000,000 shares authorized as of June 30, 2022 and December 31, 2021, respectively; 103,828,096 and 103,045,299 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively104103[1]
Additional paid-in capital1,560,6281,543,908[1]
Accumulated deficit(1,324,109)(1,135,525)[1]
Total stockholders' equity236,623408,486[1]
Total liabilities and stockholders' equity$ 470,968$ 522,396[1]
Preferred stock, par value (in dollars per share)$ 0.001$ 0.001
[1]The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date.